Phase 1 Kidney Cancer Trial, Recruiting NCT07062549 Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT07062549
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any sex who are 18 years of age or older
  • People willing to sign a consent form and follow all study requirements
  • People who have been confirmed through a tissue sample (biopsy) to have a type of kidney cancer called renal cell carcinoma (RCC) with a "clear cell" component
  • People who have between 2 and 10 areas of disease, each measuring at least 1.5 cm, visible on a contrast CT scan or MRI of the chest, abdomen, and pelvis taken within the last 60 days before joining the study
  • People whose recent blood test results meet specific levels for liver function, kidney function, and blood cell counts (confirm exact values with trial site)

Who may not be able to join:

  • People who have received systemic treatment (such as medication given throughout the body) for this type of kidney cancer within the past 12 months
  • People who have received a radioactive substance within a certain time period before the study injection (based on the substance used — confirm timeframe with trial site)
  • People with a medical condition or situation that, in the study doctor's opinion, could affect the reliability of the study results or the person's ability to complete the trial
  • Women who could become pregnant and do not have a negative pregnancy test taken within 24 hours before the imaging day
  • Women who are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yasser Ged, MBBS, Johns Hopkins University SKCCC

Phone: 410-955-8893

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
26 January 2022
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov